The 2021 update of China’s Regulation on Supervision and Administration of Medical Devices largely retains the structure of the 2014 version, while bringing some important changes for companies marketing in China.
A major change is that device companies focused on R&D will henceforth more easily be able to contract out the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?